We’re In The News

As a respected nonprofit health research center, our views are often quoted in the media, including newspapers, magazines, TV, radio, and websites. We also write articles and blogs for a number of different and highly respected newspapers, magazines, and popular websites, and we are published in prestigious medical journals and health policy publications. We frequently express our policy views in letters to government officials and public comments to federal agencies and we sometimes release statements or press releases on newsworthy issues.

Please e-mail info@center4research.org or call 202-223-4000 with your inquiries. We can assist you with scheduling interviews with the NCHR President, Dr. Diana Zuckerman, and other experts on our staff.

Critics See Accountability Risk If FDA Rule Changes Take Hold

Star Tribune, February 14, 2016. A move to relax labeling requirements for drugs and medical devices has some patient advocates concerned that people will have a tougher time holding manufacturers accountable for injuries caused by their products.

FDA Aims to Speed Clinical Trials and Improve Device Safety Through Post-Market Evaluation

Inside Health Policy, February 16, 2016. FDA’s device center chief Jeff Shuren highlighted the benefit a robust National Device Evaluation System could have in bolstering the agency’s ability to monitor devices in real-time.

FDA is Failing to Properly Track Drugs

Legalreader, February 8, 2016. Federal investigators from the Government Accountability Office (GAO) came to the conclusion that the FDA is not doing well at one of its main responsibilities.

Could This Opioid Implant Really End the Opioid Epidemic?

Buzzfeed, February 8, 2016. NCHR’s Dr. Rupp comments on Probuphine, a six-month implant of buprenorphine for addicts who are “stable” in their recovery from prescription painkiller addiction.

Is ‘Female Viagra’ Feminist?

In These Times, February 3, 2016. It’s been called the first “Viagra for women” and hailed as a health breakthrough. But Addyi (generic name flibanserin) is sparking ire just as it claims to spark desire. Since the FDA approved Addyi in August 2015, feminist debate on these questions has raged.